Press Releases September 1, 2026 08:00 AM

Voyager to Present at Upcoming Investor Conferences

Voyager Therapeutics Scheduled for Multiple Key Healthcare Investor Conferences in September 2026

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
VYGR

Voyager Therapeutics, a biotechnology company focused on genetic treatments for neurological disorders, announced participation in several upcoming investor conferences including Wells Fargo, Cantor, Morgan Stanley, Baird, and H.C. Wainwright. The company will hold multiple fireside chats to discuss its pipeline and partnerships, with a webcast available for the Wells Fargo event.

Voyager to Present at Upcoming Investor Conferences
VYGR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Voyager Therapeutics will present at five prominent healthcare investor conferences in September 2026, enhancing visibility among investors.
  • The company's pipeline targets major neurological diseases including Alzheimer's, Parkinson's, ALS, and Friedreich’s ataxia, leveraging its TRACER™ AAV capsid platform.
  • Voyager collaborates with notable partners like Alexion (AstraZeneca Rare Disease), Novartis, and Neurocrine Biosciences, indicating strong industry alliances.
  • The biotechnology and healthcare sectors—including genetic medicine and neurological disease treatment markets—are primarily impacted by these developments.

LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:

  • Wells Fargo 21st Annual Healthcare Conference: Fireside chat at 3:45 p.m. ET on Tuesday, September 8, 2026, in Boston, MA.
  • 2026 Cantor Global Healthcare Conference: Fireside chat at 8:35 a.m. ET on Friday, September 11, 2026, in New York, NY.
  • Morgan Stanley 24th Annual Global Healthcare Conference: Fireside chat at 10:45 a.m. ET on Monday, September 14, 2026, in New York, NY.
  • Baird’s 2026 Global Healthcare Conference: Fireside chat at 7:55 a.m. ET on Tuesday, September 15, 2026, in New York, NY.
  • H.C. Wainwright 28th Annual Global Investment Conference: Fireside chat at 2:30 p.m. ET on Tuesday, September 15, 2026, in New York, NY.

A webcast of the Wells Fargo fireside chat will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of the webcast will be archived on the company’s website for at least 30 days.

About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit http://www.voyagertherapeutics.com.

Voyager Therapeutics® is a registered trademark, and TRACER™ and Voyager NeuroShuttle™ are trademarks, of Voyager Therapeutics, Inc.

Contacts
Company and Investors: Trista Morrison, NACD.DC, [email protected]
Media: Lisa Guiterman, [email protected]


Risks

  • Uncertainty around pipeline program success and timing, typical in biotechnology drug development, may affect future valuations.
  • Dependence on partnerships and collaborations could present risks if any agreements are terminated or underperform.
  • General market conditions and investor reception to presentations and announcements may influence Voyager's stock volatility.

More from Press Releases

Zhihu Inc. Announces Proposed Subscription in AI-Focused Investment Fund Sep 6, 2026 Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call Sep 6, 2026 Verizon Waives Charges for Hurricane Lowell, Prepares Network in Hawai'i Sep 5, 2026 Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen Sep 4, 2026 Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Increase in August 2026 of 0.5% Compared to 2025 Sep 4, 2026